AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN ANTONIO -- The incidence of venous thromboembolism in the year following breast cancer diagnosis is roughly 1%, Dr. Helen K. Chew reported at a breast cancer symposium sponsored by the Cancer Therapy and Research Center.
That's a lower figure than previously reported in some clinical trials. But the trials typically feature lengthy exclusion criteria and involve hundreds of patients, whereas Dr. Chew's data carry the authority of big numbers: to be exact, all 108,255 women with breast cancer diagnosed in California during a 4-year period and followed through the California Cancer Registry and California Patient Discharge Data set.
By far the strongest predictor of venous thromboembolism (VTE) in this cohort was the presence of metastatic disease at breast cancer diagnosis. It was associated with a 6.3-fold increased risk, compared with patients who had localized cancer, said Dr. Chew, director of the breast cancer program at the University of California, Davis, cancer center.
The incidence of VTE was 0.6% in the first 6 months following breast cancer diagnosis and a cumulative 0.9% at the 12-month mark. It fell off thereafter such that the cumulative 2-year incidence was 1.2%.
In a multivariate analysis, ...